Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Do Hedge Funds and Insiders Love Argan, Inc. (AGX)?

Page 1 of 2

Is Argan, Inc. (NYSEAMEX:AGX) a worthy stock to buy now? The best stock pickers are in an optimistic mood. The number of bullish hedge fund positions increased by 4 recently.

Argan, Inc. (NYSEAMEX:AGX)

In today’s marketplace, there are tons of methods shareholders can use to watch the equity markets. A couple of the most underrated are hedge fund and insider trading activity. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the best hedge fund managers can trounce the market by a healthy margin (see just how much).

Equally as integral, positive insider trading sentiment is another way to parse down the world of equities. As the old adage goes: there are lots of incentives for an upper level exec to get rid of shares of his or her company, but just one, very clear reason why they would buy. Several academic studies have demonstrated the useful potential of this method if investors understand what to do (learn more here).

Keeping this in mind, it’s important to take a gander at the key action surrounding Argan, Inc. (NYSEAMEX:AGX).

How have hedgies been trading Argan, Inc. (NYSEAMEX:AGX)?

Heading into 2013, a total of 7 of the hedge funds we track were bullish in this stock, a change of 133% from the third quarter. With hedgies’ sentiment swirling, there exists an “upper tier” of notable hedge fund managers who were boosting their stakes significantly.

Of the funds we track, Jim Simons’s Renaissance Technologies had the biggest position in Argan, Inc. (NYSEAMEX:AGX), worth close to $4.8 million, accounting for less than 0.1%% of its total 13F portfolio. Sitting at the No. 2 spot is Robert B. Gillam of McKinley Capital Management, with a $1 million position; 0.1% of its 13F portfolio is allocated to the company. Other hedgies with similar optimism include Neil Chriss’s Hutchin Hill Capital, Joel Greenblatt’s Gotham Asset Management and Mike Vranos’s Ellington.

Now, specific money managers were leading the bulls’ herd. Hutchin Hill Capital, managed by Neil Chriss, assembled the most valuable position in Argan, Inc. (NYSEAMEX:AGX). Hutchin Hill Capital had 0.9 million invested in the company at the end of the quarter. Joel Greenblatt’s Gotham Asset Management also made a $0.6 million investment in the stock during the quarter. The other funds with new positions in the stock are Mike Vranos’s Ellington, Steven Cohen’s SAC Capital Advisors, and Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital.

How have insiders been trading Argan, Inc. (NYSEAMEX:AGX)?

Insider buying is most useful when the company we’re looking at has seen transactions within the past six months. Over the latest 180-day time period, Argan, Inc. (NYSEAMEX:AGX) has experienced zero unique insiders purchasing, and 1 insider sales (see the details of insider trades here).

Let’s go over hedge fund and insider activity in other stocks similar to Argan, Inc. (NYSEAMEX:AGX). These stocks are Layne Christensen Company (NASDAQ:LAYN), Great Lakes Dredge & Dock Corporation (NASDAQ:GLDD), Matrix Service Co (NASDAQ:MTRX), Orion Marine Group, Inc. (NYSE:ORN), and Sterling Construction Company, Inc. (NASDAQ:STRL). This group of stocks are in the heavy construction industry and their market caps match AGX’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!